Clinical trials: Lipid Disorders
Hyperlipoproteinemia Type II, Hypercholesterolemia, Familial
Study to Assess the Tolerability and Efficacy of Anacetrapib (MK-0859) Co-Administered With Statin in Participants With Heterozygous Familial Hypercholesterolemia (MK-0859-020)
The objective of this study is to evaluate the efficacy and tolerability of adding anacetrapib to ongoing statin therapy in participants with heterozygous familial hypercholesterolemia (HeFH).
- Trial name
- REALIZE (NCT01524289)
- Testing
- Anacetrapib
- Volunteers
- 306 people
- Sponsor
- Merck Sharp & Dohme LLC
Body Fat Disorder
CoolSculpting in the Abdomen Using Applicator With and Without CCI
Evaluate the safety and efficacy of non-invasive subcutaneous fat layer reduction in the abdomen using an applicator with the Crown Cooling Insert.
- Trial name
- CCI (NCT02787850)
- Testing
- CoolSculpting Treatment
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Zeltiq Aesthetics
Atherosclerosis, Coronary Artery Disease
MARS - Monitored Atherosclerosis Regression Study
The purpose of this study is to determine whether significant alterations in serum lipoproteins as provided by the drug lovastatin can substantially reduce atherosclerosis progression or even induce regression.
- Trial name
- NCT00116870
- Testing
- lovastatin
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- Merck Sharp & Dohme LLC
Homozygous Familial Hypercholesterolemia
Phase 3 Study to Evaluate the Efficacy and Safety of LIB003 With Evolocumab in HoFH
To compare the safety, tolerability and LDL-C response after 24 Weeks of monthly (every 4 weeks [Q4W]) subcutaneous (SC) dosing of LIB003 300 mg with monthly (Q4W) SC dosing of 420 mg evolocumab (Repatha®) in patients with HoFH…
- Trial name
- NCT04034485
- Testing
- lerodalcibep, evolocumab
- Where
- 12 sites in United States, India and 4 more
- Volunteers
- 65 people
- Sponsor
- LIB Therapeutics LLC
Familial Hypercholesterolemia
Effect of APL180 on Endothelial Function in Familial Hypercholesterolemia Patients
This study will evaluate the effect of APL180 on endothelial function measured by forearm venous occlusion plethysmography in patients with familial hypercholesterolemia.
- Trial name
- NCT00751608
- Testing
- APL180
- Sponsor
- Novartis Pharmaceuticals
Severe Familial Hypercholesterolemia
Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
A study to assess the long term safety and tolerability of evolocumab (AMG 145) in adolescents and adults with severe familial hypercholesterolemia.
- Trial name
- TAUSSIG (NCT01624142)
- Testing
- Evolocumab
- Where
- 44 sites in United States, Australia and 16 more
- Volunteers
- 300 people
- Sponsor
- Amgen
Hypercholesterolaemia
An Efficacy and Safety Study of Akkermansia Muciniphila AKM Lab-01 in Hypercholesterolaemia
The purpose of this study was to assess the safety and efficacy of AKM Lab-01 in subjects with hypercholesterolemia. This study will be conducted as a randomized, double-blind, placebo-controlled trial, eligible…
- Trial name
- AKM Lab-01 (NCT06974266)
- Testing
- Probiotic
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Moon (Guangzhou) Biotechnology Co., Ltd.
Type II Diabetes Mellitus, Dyslipidemia
Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined Dyslipidemia
The purpose of this study is to compare the efficacy and safety of pitavastatin with that of atorvastatin in patients with type II diabetes mellitus (type II DM) and combined dyslipidemia.
- Trial name
- NCT00309751
- Testing
- Pitavastatin, Atorvastatin
- Where
- 35 sites in Denmark, Germany and 4 more
- Volunteers
- 418 people
- Sponsor
- Kowa Research Europe
Severe Hypertriglyceridemia
A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia
This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial for adults with severe hypertriglyceridemia whose lipid levels remain uncontrolled under standard Icosapent Ethyl background treatment plus…
- Trial name
- NCT07680829
- Testing
- DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule
- Where
- 2 sites in China
- Volunteers
- 378 people
- Sponsor
- Zhejiang Doer Biologics Co., Ltd.
Hyperlipidemia
A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjects
It is a randomized, double-blind, single-dose, placebo-controlled phase I clinical trial. The study plans to conduct four to six dose groups of dose 1, dose 2, dose 3, dose4, dose5 (optional), and dose 6(optional).
- Trial name
- NCT06541457
- Testing
- HRS-7249 injection
- Where
- China
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.
Dyslipidemia
Safety Study of BMS-770767 in Subjects With Hypercholesterolemia
The purpose of this study is to assess the safety, tolerability and pharmacodynamic effects on LDL cholesterol (LDL-C)
- Trial name
- NCT01058083
- Testing
- BMS-770767
- Where
- 14 sites in United States, Australia and 1 more
- Volunteers
- 81 people
- Sponsor
- Bristol-Myers Squibb
Hypercholesterolemia
A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia
This study will assess the safety, atorvastatin pharmacokinetics, and LDL-C lowering efficacy of ETC-1002 versus placebo in hypercholesterolemic subjects on background therapy of atorvastatin 10 mg.
- Trial name
- NCT01779453
- Testing
- ETC-1002, Atorvastatin
- Where
- 3 sites in United States
- Volunteers
- 58 people
- Sponsor
- Esperion Therapeutics, Inc.
Healthy
A Phase 1 Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Escalating Single and Multiple-Dose Study of Aramchol in Healthy Male Volunteers. Primary Objectives: 1.
- Trial name
- NCT00776841
- Testing
- Aramchol
- Where
- Israel
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Galmed Medical Reserch
Dyslipidemias
A Phase III Long Term Study of K-877 Extended Release Tablet
To investigate the safety and efficacy of K-877 Extended Release (ER) once daily for 52 weeks in the morning or evening in dyslipidema.The starting dose of the ER tablet will be 0.2 mg/day.
- Trial name
- NCT04716595
- Testing
- K-877 ER 0.2 mg/day morning administration (once daily), K-877 ER 0.2 mg/day evening administration (once daily)
- Where
- 14 sites in Japan
- Volunteers
- 121 people
- Sponsor
- Kowa Company, Ltd.
Homozygous Familial Hypercholesterolemia
Study to Evaluate the Effects of MBX-8025 in Patients With HoFH
A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH).
- Trial name
- NCT02472535
- Testing
- MBX-8025 50 mg (Dose Escalation Period 1), MBX-8025 50 mg or 100 mg (Dose Escalation Period 2), MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)
- Where
- 5 sites in Canada, France and 2 more
- Volunteers
- 13 people
- Sponsor
- Gilead Sciences
Diabetes Mellitus, Type 2
Effect of Metformin on Gut Peptides , Bile Acids and Lipid Profiles in Type 2 Diabetics
Metformin is a biguanide that is marketed as an oral anti-diabetic drug. Metformin treatment in concert with diet and exercise is the consensus first-line treatment for type 2 diabetes mellitus (T2DM), and therefore it will…
- Trial name
- NCT01357876
- Testing
- Metformin
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- GlaxoSmithKline
Dyslipidemia
Study to Assess PK/PD Character, Safety/Tolerability of CKD-519 New Formulation in Healthy Male Subject.
Study to assess the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability to CKD-519 new formulation in healthy male subjects.
- Trial name
- NCT02623868
- Testing
- CKD-519 50mg 2Tabs., CKD-519 100mg 1Tab., CKD-519 100mg 1Cap.
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Hyperlipidemia, Hypertriglyceridemia
Phase I Drug-drug Interaction of Omega-3 and Atorvastatin
This study evaluates the safety and pharmacokinetic drug-drug interactions of omega-3 and atorvastatin in healthy male volunteers.
- Trial name
- NCT03438955
- Testing
- Omacor, Pritor, Omacor + Pritor
- Where
- South Korea
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- DongKoo Bio & Pharma
Hypertension and Dyslipidemia
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mg
A Clinical Trial to evaluate the Pharmacokinetics and Tolerability of CKD-386(5)
- Trial name
- NCT05698043
- Testing
- CKD-386(5), D013, D326, D337
- Where
- South Korea
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Chong Kun Dang Pharmaceutical
Cardiovascular Diseases
Evaluation of Atorvastatin Treatment on Carotid Plaque.
The purpose of the study is to evaluate the effect of 18 months treatment with atorvastatin 80mg or atorvastatin 10mg on the carotid vessel plaque morphology, in particular, the effect on evident necrotic lipid rich core of the…
- Trial name
- NCT00343655
- Testing
- Atorvastatin
- Where
- United States
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.